Key result
Wearable cardioverter-defibrillators provide sudden cardiac death prevention during the transient risk period associated with catheter ablation for AF-related tachycardiomyopathy.
Why the study?
ICD implantation is not indicated for transient or reversible causes of sudden cardiac death, leading to increased use of wearable cardioverter-defibrillators in patients with transient ventricular arrhythmia risk.
Does the use of a wearable cardioverter-defibrillator in association with catheter ablation prevent sudden cardiac death in patients with atrial fibrillation-related tachycardiomyopathy?
Does the use of a wearable cardioverter-defibrillator in association with catheter ablation prevent sudden cardiac death in patients with atrial fibrillation-related tachycardiomyopathy?
Wearable cardioverter-defibrillators may offer a strategy for sudden cardiac death prevention in patients with transient risk of ventricular arrhythmia due to atrial fibrillation-related tachycardiomyopathy.
May support WCD bridging for transient SCD risk post-ablation in AF-tachycardiomyopathy; hypothesis-generating and requires prospective validation.
Implantable cardioverter-defibrillator (ICD) is an effective therapy in patients known to be at high risk for sudden cardiac death (SCD). Nevertheless, ICD implantation is not indicated in transient or reversible causes of SCD. Wearable cardioverter-defibrillator is increasingly used for SCD prevention in patients with a transient risk of ventricular arrhythmia.
No takes yet. Share an insight, caveat, or question.
Conti et al. (2019) studied this question. Wearable cardioverter-defibrillators provide sudden cardiac death prevention during the transient risk period associated with catheter ablation for AF-related tachycardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: